ImmunoCAP ECP Update
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
We would like to update you with a recent brochure from Thermo Fisher Scientific on the ImmunoCAPTM ECP for quantifying eosinophil cationic protein (ECP).
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
We would like to update you with a recent brochure from Thermo Fisher Scientific on the ImmunoCAPTM ECP for quantifying eosinophil cationic protein (ECP).
Products are for professional/laboratory use only.
Abacus dx is pleased to announce the launch of the NEW CE-marked ImmunoCAP Allergen f447, Allergen component rAra h 6, Peanut
Products are for professional/laboratory use only.
In 1906, a young Austrian pediatrician – Clemens von Pirquet – suggested that the first contact with an antigen can change the immune system to induce tolerance or hypersensitive reactions upon the second follow-up contact. He called this idea ‘Allergy’.
Products are for professional/laboratory use only.
Authors: Knut Brockow1 , Lawrence B Schwartz2 1 Department of Dermatology and Allergy Biederstein, Technical University Munich, Munich, Germany 2 Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, Virginia Commonwealth University, Richmond, Virginia, USA
Products are for professional/laboratory use only.
The presentations shown at the recent Phadia User Group Meeting can be viewed via the below links:
Products are for professional/laboratory use only.
Allergy to house dust mites (HDM) is a main cause of respiratory allergies, and exposure to HDM is a major trigger of asthma exacerbations.
Products are for professional/laboratory use only.
Discover the new ImmunoCAP bee venom components
Products are for professional/laboratory use only.
ImmunoCAP ISAC, a highly advanced tool for revealing the patient’s IgE antibody profile, is yet again available to benefit a clinical practice.
Products are for professional/laboratory use only.
House dust mite allergy is a common cause of allergic asthma and allergic rhinitis. More than 130 million people are affected globally and due to the burden of disease, Allergen immunotherapy (AIT) may be considered in patients with perennial allergic rhinitis.